These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

909 related articles for article (PubMed ID: 25723109)

  • 21. Identification of
    Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
    Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
    Song Z; Yu X; Zhang Y
    Cancer Biol Ther; 2017 Nov; 18(11):883-887. PubMed ID: 27635639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC.
    Melchior L; Hirschmann A; Hofman P; Bontoux C; Concha A; Mrabet-Dahbi S; Vannuffel P; Watkin E; Putzová M; Scarpino S; Cayre A; Martin P; Stoehr R; Hartmann A
    Virchows Arch; 2024 Apr; 484(4):677-686. PubMed ID: 38492039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
    Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
    J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammatory myofibroblastic tumor and low-grade myofibroblastic sarcoma: a comparative study of clinicopathologic features and further observations on the immunohistochemical profile of myofibroblasts.
    Qiu X; Montgomery E; Sun B
    Hum Pathol; 2008 Jun; 39(6):846-56. PubMed ID: 18400254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.
    Velizheva NP; Rechsteiner MP; Valtcheva N; Freiberger SN; Wong CE; Vrugt B; Zhong Q; Wagner U; Moch H; Hillinger S; Schmitt-Opitz I; Soltermann A; Wild PJ; Tischler V
    Pathol Res Pract; 2018 Apr; 214(4):572-578. PubMed ID: 29580750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach.
    Yoon HJ; Sohn I; Cho JH; Lee HY; Kim JH; Choi YL; Kim H; Lee G; Lee KS; Kim J
    Medicine (Baltimore); 2015 Oct; 94(41):e1753. PubMed ID: 26469915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pseudosarcomatous myofibroblastic proliferations of the genitourinary tract are genetically different from nodular fasciitis and lack USP6, ROS1 and ETV6 gene rearrangements.
    Jebastin JAS; Smith SC; Perry KD; Gupta NS; Alanee S; Carskadon S; Chitale DA; Palanisamy N; Williamson SR
    Histopathology; 2018 Aug; 73(2):321-326. PubMed ID: 29617048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.
    Mariño-Enríquez A; Wang WL; Roy A; Lopez-Terrada D; Lazar AJ; Fletcher CD; Coffin CM; Hornick JL
    Am J Surg Pathol; 2011 Jan; 35(1):135-44. PubMed ID: 21164297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uterine inflammatory myofibroblastic tumors in pregnant women with and without involvement of the placenta: a study of 6 cases with identification of a novel TIMP3-RET fusion.
    Cheek EH; Fadra N; Jackson RA; Davila JI; Sukov WR; Uckerman MT; Clayton A; Keeney GL; Halling KC; Torres-Mora J; Schoolmeester JK
    Hum Pathol; 2020 Mar; 97():29-39. PubMed ID: 31917155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of ALK Fusions in Uncommon Inflammatory Myofibroblastic Tumors With ALK IHC Positivity but FISH-Equivocal Findings by Targeted RNA Sequencing.
    Yao Q; Bai Q; Zhang X; Ji G; Chang H; Cai X; Yu L; Wang J; Zhu X; Zhou X
    Arch Pathol Lab Med; 2022 Oct; 146(10):1234-1242. PubMed ID: 35041745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uterine inflammatory myofibroblastic tumor harboring novel NUDCD3-ROS1 and NRP2-ALK fusions: clinicopathologic features of 4 cases and literature review.
    Zhang L; Luan L; Shen L; Xue R; Huang J; Su J; Huang Y; Xu Y; Wang X; Shao Y; Ji Y; Xu C; Hou Y
    Virchows Arch; 2023 Mar; 482(3):567-580. PubMed ID: 36624188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer.
    Rogers TM; Arnau GM; Ryland GL; Huang S; Lira ME; Emmanuel Y; Perez OD; Irwin D; Fellowes AP; Wong SQ; Fox SB
    Sci Rep; 2017 Feb; 7():42259. PubMed ID: 28181564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
    Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
    Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in situ hybridization.
    Diks J; Tang Z; Altan M; Anderson S; Chen H; Rashid A; Yang RK; Routbort MJ; Patel KP; Toruner GA; Medeiros LJ; Tang G; Luthra R; Roy-Chowdhuri S
    Cancer Cytopathol; 2024 Jan; 132(1):41-49. PubMed ID: 37747438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor.
    Cools J; Wlodarska I; Somers R; Mentens N; Pedeutour F; Maes B; De Wolf-Peeters C; Pauwels P; Hagemeijer A; Marynen P
    Genes Chromosomes Cancer; 2002 Aug; 34(4):354-62. PubMed ID: 12112524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel TPD52L2-ROS1 gene fusion expanding the molecular alterations in inflammatory myofibroblastic tumor: case report and literature review.
    Liu X; Duan Y; Wang G; Zhu P
    Diagn Pathol; 2023 Sep; 18(1):105. PubMed ID: 37735390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
    Drilon A; Bergagnini I; Delasos L; Sabari J; Woo KM; Plodkowski A; Wang L; Hellmann MD; Joubert P; Sima CS; Smith R; Somwar R; Rekhtman N; Ladanyi M; Riely GJ; Kris MG
    Ann Oncol; 2016 Jul; 27(7):1286-91. PubMed ID: 27056998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis.
    Zhang S; Yan B; Zheng J; Zhao J; Zhou J
    Oncotarget; 2016 Sep; 7(39):63758-63766. PubMed ID: 27563816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathologic and Genomic Characterization of Inflammatory Myofibroblastic Tumors of the Head and Neck: Highlighting a Novel Fusion and Potential Diagnostic Pitfall.
    Kerr DA; Thompson LDR; Tafe LJ; Jo VY; Neyaz A; Divakar P; Paydarfar JA; Pastel DA; Shirai K; John I; Seethala RR; Salgado CM; Deshpande V; Bridge JA; Kashofer K; Brčić I; Linos K
    Am J Surg Pathol; 2021 Dec; 45(12):1707-1719. PubMed ID: 34001695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.